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Low plasma high-density lipoprotein (HDL)-cholesterol
concentration is encountered in clinical practice as part
of mixed hyperlipidaemia, hypertriglyceridaemia, or as an
isolated abnormality. Low HDL-cholesterol is common
among patients with premature coronary artery disease
(CAD) [1]. The cardioprotective effect of HDL-cholesterol
is well supported by both observational and experimental
studies [2]. Although the favourable effect of lowering
elevated plasma low-density lipoprotein (LDL)-cholesterol
has been well emphasized [3–5], the therapeutic benefits
of raising low HDL-cholesterol has only recently been
demonstrated in clinical trials. The present review
describes the evidence and implications of these recent
trials, and places them into the wider context of the man-
agement of patients with low HDL-cholesterol.
Recent trials of raising low high-density
lipoprotein cholesterol
Table 1 compares the characteristics and outcomes of
three clinical trials that employed a fibrate or a statin in
patients with low plasma HDL-cholesterol [6–8]. Veter-
ans Affairs HDL-Cholesterol Intervention Trial (VA-HIT) [6]
was a secondary prevention study that examined the
effect of gemfibrozil (1200 mg/day) on the combined
incidence of nonfatal myocardial infarction and death
from CAD in middle-aged men. Many patients exhibited
the metabolic syndrome (obesity, dyslipidaemia, hyper-
tension, insulin resistance), and 25% had diabetes. The
trial was carried out over a mean period of 5 years. The
Bezafibrate Infarction Prevention (BIP) study [7] was a
secondary prevention study of the effect of bezafibrate
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retard (400 mg/day) on myocardial infarction and sudden
death in middle-aged persons, most of whom were men
and 10% of whom had diabetes. It lasted for approxi-
mately 6 years. The Air Force/Texas Coronary Atheroscle-
rosis Prevention Study (AFCAPS/TexCAPS) [8] was a
primary prevention trial of the effect of lovastatin
(20–40 mg/day) on first major acute coronary events in
middle-aged persons, most of whom were male and only
3% of whom had diabetes. Its duration was approxi-
mately 5 years.
The entry plasma HDL-cholesterol level was lower in VA-HIT
than in the BIP study and AFCAPS/TexCAPS, and the LDL-
cholesterol at entry in the latter two trials was approximately
1 mmol/l higher than in the VA-HIT population. VA-HIT also
included older patients, and more of these had diabetes,
hypertension and obesity, and were current smokers. As
shown in Table 1, the percentage increase in HDL-
cholesterol was similar in VA-HIT and AFCAPS/TexCAPS,
but significantly less than in the BIP study. The dominant
plasma lipid changes were a reduction in triglycerides in
VA-HIT and a reduction on LDL-cholesterol in AFCAPS/
TexCAPS – changes that are consistent with the effects of
a fibrate and statin, respectively. In the BIP study the reduc-
tion in triglycerides was less than in VA-HIT, but a greater
increase in HDL-cholesterol was seen with bezafibrate than
with gemfibrozil.
Risk reduction, subsets and other trials
Although the relative risk reduction in the primary end-
point was greater in AFCAPS/TexCAPS than in VA-HIT,
the absolute risk reduction was greater in the latter than
the former trial. This is consistent with the differences in
background risk of CAD between the study populations.
The overall relative risk reduction in the primary end-point
in the BIP study was not statistically significant. In patients
with entry plasma triglycerides in excess of 2.25 mmol/l,
however, there was a significant 40% reduction in relative
Table 1
Comparison of recent clinical end-point trials that employed a fibrate (VA-HIT, BIP) or a statin (AFCAPS/TexCAPS) in patients with
low plasma HDL-cholesterol
Trial
VA-HIT BIP AFCAPS/TexCAPS
Drug Gemfibrozil Bezafibrate Lovastatin
Indication Secondary prevention Secondary prevention Primary prevention
Duration (years) 5.2 6.2 5.2
Primary end-point Nonfatal myocardial infarction/ Myocardial infarction/ Acute major coronary event
CAD mortality sudden death
Patient characteristics
Age (years) 64 60 58
n (male/female) 2531/0 2825/265 5608/997
Diabetes (%) 25 10 3
Hypertension (%) 57 32 22
Current smokers (%) 20 12 12
Total cholesterol (mmol/l) 4.5 5.6 5.7
Triglycerides (mmol/l) 1.8 1.6 1.8
LDL-cholesterol (mmol/l) 2.9 3.9 3.9
HDL-cholesterol (mmol/l) 0.8 0.9 0.9
Outcome variables
Total cholesterol (%) –6 –4 –18
Triglycerides (%) –31 –21 –15
LDL-cholesterol (%) –4 –6 –25
HDL-cholesterol (%) +6 +18 +6
Effect of treatment on primary end-point
Relative risk reduction (%) –22 –9 –37
Absolute risk reduction (%) –4.4 –1.4 –2.0
NNT to prevent an event 23 71* 50†
*NNT = 12 for patients with baseline triglycerides greater than 2.25 mmol/l. †NNT = 125 for patients with baseline HDL-cholesterol greater than
0.9 mmol/l.Current Controlled Trials in Cardiovascular Medicine    June 2001 Vol 2 No 3 Watts
risk, with a corresponding 8% decrease in the absolute
risk. After 5 years the incidence curve of the primary end-
point appeared to level off in the placebo group in the BIP
study, and this might have been related to the use of
open-label statin therapy by primary care physicians [9].
In VA-HIT the number of patients needed to treat (NNT) to
prevent one event over the duration of the trial was
approximately 24. This compares favourably with the
5-year NNT to prevent one fatal myocardial infarction/
death from CAD of 33 and 28 in Cholesterol and Recur-
rent Events (CARE) [10] and Long-term Intervention with
Pravastatin in Ischaemic Disease (LIPID) [11], respec-
tively, two trials that employed pravastatin. The NNT for
persons with triglycerides greater than 2.25 mmol/l was
12 in the BIP study [9], which was significantly less than
the NNT of 42 in patients with triglycerides greater than
2.42 mmol/l in the Helsinki Heart Study (HHS) [12]; this is
consistent with the secondary and primary prevention set-
tings of these trials, respectively. In AFCAPS/TexCAPS
the overall NNT to prevent one event was 50, and this was
chiefly attributable to patients with a baseline HDL-choles-
terol below 0.9 mmol/l [13], in whom the relative risk
reduction of cardiovascular events was 45%; this was sig-
nificantly greater than for those with a baseline HDL cho-
lesterol greater than 1.08 mmol/l. The overall efficacy of
lovastatin in AFCAPS/TexCAPS is similar to that of
pravastatin in the West of Scotland Coronary Pravastatin
Study (WOSCOPS) [14], an earlier primary prevention
trial in hypercholesterolaemic patients.
Mechanisms of benefit
The mechanisms of the benefits of fibrates and statins in
the above trials is not clear, although angiographic data
[15–17] support the notion of regression of atherosclero-
sis. Because statins and fibrates not only increase plasma
HDL, but also lower the concentration of other proathero-
genic lipoproteins, such as LDL and remnants, it is not
possible to ascertain how much of the benefit seen in the
trials is attributable to the increase in HDL [9].
The greatest relative risk reduction in AFCAPS/TexCAPS,
however, was seen in patients with a baseline HDL-
cholesterol below 0.9 mmol/l, with the on-treatment
apolipoprotein B to apolipoprotein A1 ratio being the most
significant predictor of subsequent coronary risk [13]. An
independent treatment effect on outcomes was not specif-
ically identified in this analysis of the trial, but is likely to
have been operational [18]. In VA-HIT multivariate analysis
[19] showed that only on-trial HDL-cholesterol and treat-
ment group assignment predicted coronary events at
5 years; the lowest coronary event rate was seen in
patients with on-treatment HDL-cholesterol in excess of
0.9 mmol/l. However, only 23% of the benefit achieved
with gemfibrozil could be explained by the on-treatment
plasma levels of HDL-cholesterol, triglycerides and
LDL-cholesterol. Hence, it is possible that the pleiotropic
effects shared by fibrates and statins that directly inhibit
atherogenesis and thrombogenesis may be responsible
for the reduction in coronary events in the trials reviewed
here [18,20]. It is likely, but unproven, that the cardio-
vascular benefits seen with gemfibrozil and lovastatin in
normocholesterolaemic low-HDL populations reflect a
class effect of fibrates and statins, respectively. 
Clinical implications
The VA-HIT results therefore suggest that when LDL-
cholesterol levels are optimal, or near optimal, increasing
HDL-cholesterol with reduction in triglyceride-rich lipopro-
teins may be a cost-effective approach to decreasing the
incidence of coronary events in secondary prevention. The
BIP subgroup analysis shows that, in hypertriglyceri-
daemic persons with coronary disease, bezafibrate is a
cost-effective treatment for dyslipidaemia if triglycerides
levels are greater than 2.2 mmol/l, despite the background
risk being less than in patients included in VA-HIT. The
AFCAPS/TexCAPS results have implications for primary
prevention in the general population, and in particular for
individuals with low HDL-cholesterol in whom the
increased risk of coronary disease appears to be dimin-
ished. Significantly, in AFCAPS/TexCAPS only 17% of the
patients in the trial met National Cholesterol Education
Program LDL-cholesterol cut-points for the initiation of
statin therapy [3]. In all the trials reviewed, the safety of
fibrate and statin therapies was reaffirmed.
Managing low high-density lipoprotein
cholesterol
Lifestyle and pharmacotherapy
The initial approach to treating low HDL-cholesterol
should involve lifestyle modification, including cessation of
cigarette smoking, weight reduction, regular physical exer-
cise and possibly a moderate regular intake of alcohol
[21]. In secondary prevention, if this metabolic abnormality
is not corrected nonpharmacologically, then a statin
should be employed initially to lower LDL-cholesterol to
below 2.6 mmol/l; if HDL still remains below 0.9 mmol/l
with or without elevation of triglycerides, then the trial evi-
dence supports employing a fibrate as adjunctive therapy.
However, the benefit of fibrates in patients whose LDL has
been reduced by statins has not been formally demon-
strated. If LDL-cholesterol is initially below 3.4 mmol/l,
then a fibrate may be used as first-line therapy, especially
if triglycerides are also greater than 1.6 mmol/l [22], with
the option of adding a statin later if the LDL-cholesterol
remains above 2.6 mmol/l. Again, this remains to be
specifically corroborated in a clinical trial, but the advice
given is consistent with existing evidence.
Broadly similar recommendations could apply to primary
prevention in patients with multiple cardiovascular risk
factors, and this may be particularly pertinent to asympto-matic patients with type 2 diabetes or visceral obesity
[23,24]. The value of treating diabetic patients with feno-
fibrate is presently being addressed in the Fenofibrate in
Event Lowering in Diabetes (FIELD) trial, and the role of
statins in the Heart Protection Study (HPS) and the Col-
laborative Atorvastatin in Diabetes Study (CARDS) [9].
Hypertensive patients in routine practice are likely to have
the metabolic syndrome or diabetes, and constitute a
special group that merits fibrate or statin treatment in
order to raise coexistent low HDL levels.
However, whether there is incremental benefit in both
primary and secondary prevention settings of employing a
fibrate together with a statin in treating patients with low
HDL-cholesterol remains to be rigorously demonstrated.
This issue is being addressed in diabetic patients in the
Oxford-based Lipids in Diabetes Study (LDS) [9].
Although niacin is the most potent agent for raising HDL
levels and trial evidence suggests that it may decrease
coronary events in hyperlipidaemic patients with previous
myocardial infarction [25], it has never been tested in pop-
ulations similar to those in VA-HIT and AFCAPS/
TexCAPS. Tolerability and adherence is a major problem
with niacin. The efficacy of the new niacin formulations as
monotherapy and combined therapy for patients with low
HDL levels needs to be confirmed in clinical trials with car-
diovascular end-points. Caution should be exercised when
employing combination therapy of fibrates or niacin with
statins, because of potential hepatotoxicity and myopathy;
close monitoring of liver and muscle enzymes is therefore
recommended. Finally, many patients with low HDL levels
will have diabetes and insulin resistance [9], so that
another important question for future trials is whether met-
formin or thiazolidinediones confer cardiovascular benefit
over and above that due to lipid-regulating therapy.
Concerning women
Although a similar strategy for managing low HDL-choles-
terol is at present recommended for both men and
women, the specific use of oestrogen in postmenopausal
women merits consideration. Oestrogen supplementation
is well recognized to increase plasma HDL-cholesterol
effectively [26], but it also increases triglycerides, and this
may explain its lack of benefit on CAD risk in clinical trials
[27]. The potential synergistic benefit of oestrogen
replacement, including selective oestrogen receptor mod-
ulators, and that of other pharmacotherapies for increasing
HDL requires further research.
Other considerations
Finally, in hypertensive patients with low HDL that is
refractory to the aforementioned therapies, consideration
should be given to employing a-blockers, such as prazosin
and doxazosin. However, the efficacy of a-blockers alone
and in combination with other agents that elevate HDL-
cholesterol still needs to be demonstrated in clinical end-
point trials. Recent findings from the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) [28] have also cast some doubt on the use of
doxazosin. Drug and gene therapies that selectively
elevate HDL are under development [29], and may eventu-
ally find a place in clinical practice.
Conclusion
Translation of the trial data presented above into effective
clinical management requires more accurate methods for
assessing cardiovascular risk and reconsideration of the
optimal therapeutic targets for plasma lipid and lipoprotein
levels [9,22,30]. Although the guidelines for total choles-
terol and LDL-cholesterol in risk assessment are well
established [3–5], treatment recommendations concern-
ing HDL-cholesterol are not as rigorous or aggressive.
Failure to recognize HDL in assessing patients signifi-
cantly underestimates their risk of CAD [31]. Also, mea-
suring triglycerides has not generally been recommended
in risk assessment, but its inclusion may be critical in
patients with visceral obesity, hypertension and diabetes
[9,30]. Serial, fasting blood tests will provide a more
precise evaluation of triglyceride-mediated cardiovascular
risk, particularly in the presence of an elevated HDL-
cholesterol.
Given the results of VA-HIT and related studies, the
National Cholesterol Education Program guidelines of a
triglycerides level below 2.2 mmol/l and an HDL-choles-
terol greater than 1 mmol/l as ‘normal’ certainly need to be
reviewed [3]. Of relevance, data from the Prospective Car-
diovascular Munster (PROCAM) Heart Study suggest that
plasma triglycerides should be lowered to below
1.1 mmol/l and HDL increased to above 1.2 mmol/l in
high-risk individuals to prevent coronary events [32,33],
which is consistent with the aggregate findings of the
trials reviewed here. Accordingly, expert bodies need to
review their guidelines for assessing and treating plasma
triglycerides and HDL-cholesterol levels [3–5]. Some con-
sideration should also be given to employing apolipopro-
teins B and A1 in risk assessment and treatment, based
on the AFCAPS/TEXCAPS findings [13].
Finally, for many patients with low HDL-cholesterol, treat-
ment with statins and fibrates will need to be comple-
mented with lifestyle changes and other drugs, including
antihypertensive and antidiabetic agents. Ensuring patient
adherence to all of these potentially effective measures
probably remains the major challenge for the prevention
and reversal of CAD.
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